Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications
AREG	374	CRIZOTINIB	CHEMBL601719		CIViC	21791641
AREG	374	CETUXIMAB	CHEMBL1201577		CIViC	23374602
AREG	374	PANITUMUMAB	CHEMBL1201827		CIViC	26867820

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
AREG	rs10034692	GG	cetuximab	efficacy	no	No significant difference in disease control rate was seen between the genotype groups. Using the Response Evaluation Criteria in Solid Tumors (RECIST), disease control rate was the percentage of patients with complete response, partial response or stable disease (as opposed to patients with progressive disease).	Genotype GG is not associated with response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to genotypes AA + AG.	23959273	1184510781
AREG	rs3913032	CC	cetuximab	efficacy	no	No significant difference in disease control rate was seen between the genotype groups. Using the Response Evaluation Criteria in Solid Tumors (RECIST), disease control rate was the percentage of patients with complete response, partial response or stable disease (as opposed to patients with progressive disease).	Genotype CC is not associated with response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to genotypes AA + AC.	23959273	1184510773
AREG	rs6447003	CC	cetuximab	efficacy	no	No significant difference in disease control rate was seen between the genotype groups. Using the Response Evaluation Criteria in Solid Tumors (RECIST), disease control rate was the percentage of patients with complete response, partial response or stable disease (as opposed to patients with progressive disease).	Genotype CC is not associated with response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to genotypes CG + GG.	23959273	1184510777
AREG	rs9996584	AA	cetuximab	efficacy	yes	Patients with the AA genotype showed significantly higher disease control rate (89%) as compared to those with the AC (80%) or CC (60%) genotype. Using the Response Evaluation Criteria in Solid Tumors (RECIST), disease control rate was the percentage of patients with complete response, partial response or stable disease (as opposed to patients with progressive disease). Please note alleles have been complemented to the plus chromosomal strand.	Genotype AA is associated with increased response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to genotypes AG + GG.	23959273	1184510644
AREG	rs11725706	GG	cetuximab	efficacy	no	No significant difference in disease control rate was seen between the genotype groups. Using the Response Evaluation Criteria in Solid Tumors (RECIST), disease control rate was the percentage of patients with complete response, partial response or stable disease (as opposed to patients with progressive disease).	Genotype GG is not associated with response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to genotypes AA + AG.	23959273	1184510785
AREG	rs13104811	GG	cetuximab	efficacy	yes	Patients with the GG genotype showed significantly higher disease control rate (100%) as compared to those with the AA or AG (70%) genotype. Using the Response Evaluation Criteria in Solid Tumors (RECIST), disease control rate was the percentage of patients with complete response, partial response or stable disease (as opposed to patients with progressive disease).	Genotype GG is associated with increased response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to genotypes AA + AG.	23959273	1184510631
AREG	rs11942466	AA + AC	capecitabine	efficacy	yes	p-value and OR below for multivariate analysis. In univariate analysis, 35.7% of those with the CC genotype achieved pathological complete response, compared with 19.4% of those with the AC genotype and 0% of those with the AA genotype.	Genotypes AA + AC is associated with decreased response to capecitabine and radiotherapy in people with Rectal Neoplasms as compared to genotype CC.	25026457	1444934680
AREG	rs11942466	AA	cetuximab	efficacy	yes	Patients with the AA genotype showed significantly lower disease control rate (25%) as compared to those with the AC (72%) or CC (85%) genotype. Using the Response Evaluation Criteria in Solid Tumors (RECIST), disease control rate was the percentage of patients with complete response, partial response or stable disease (as opposed to patients with progressive disease).	Genotype AA is associated with decreased response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to genotypes AC + CC.	23959273	1184510640
AREG	rs1353295	GG	cetuximab	efficacy	yes	Patients with the GG genotype showed significantly higher disease control rate (100%) as compared to those with the AA or AG (72%) genotype. Using the Response Evaluation Criteria in Solid Tumors (RECIST), disease control rate was the percentage of patients with complete response, partial response or stable disease (as opposed to patients with progressive disease).	Genotype GG is associated with increased response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to genotypes AA + AG.	23959273	1184510648
AREG	rs2132065	AA	cetuximab	efficacy	no	No significant difference in disease control rate was seen between the genotype groups. Using the Response Evaluation Criteria in Solid Tumors (RECIST), disease control rate was the percentage of patients with complete response, partial response or stable disease (as opposed to patients with progressive disease).	Genotype AA is not associated with response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to genotypes AT + TT.	23959273	1184510789